Idelevich Efraim, Mozes Marta, Ben-Baruch Noa, Huszar Monica, Kruglikova Anna, Katsnelson Rivka, Shani Adi
Institutes of Oncology, Kaplan Medical Center, Rehovot, Israel.
Am J Clin Oncol. 2003 Jun;26(3):259-61. doi: 10.1097/01.COC.0000020582.25017.5D.
The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53, and bcl-2 were immunohistochemically stained on sections from formalin-fixed, paraffin-embedded tissues. Seventeen (56.7%) of the 30 cases of MBC were bcl-2 positive. Few specimens were found positive for c-erbB-2 (6.7%) and p53 (6.7%). The 5-year survival rate was marginally better for those patients with tumors staining positively for bcl-2 (p = 0.05). It was impossible to estimate the association between survival rate and p53 and c-erbB-2 expression because of the small number of positively stained specimens. In this study, only bcl-2 showed marginal association to other tumor parameters and a trend toward a better 5-year survival rate. At present there is inadequate evidence to support the use of molecular markers as independent prognostic markers in MBC.
本研究的目的是评估c-erbB-2、p53和bcl-2在男性乳腺癌（MBC）中的表达程度及其预后意义。对30例诊断为乳腺腺癌的男性患者进行了回顾性研究。所有患者均接受了手术；对福尔马林固定、石蜡包埋组织切片进行c-erbB-2、p53和bcl-2免疫组化染色。30例MBC病例中有17例（56.7%）bcl-2呈阳性。发现很少有标本c-erbB-2（6.7%）和p53（6.7%）呈阳性。bcl-2染色阳性的肿瘤患者5年生存率略高（p = 0.05）。由于阳性染色标本数量较少，无法评估生存率与p53和c-erbB-2表达之间的关联。在本研究中，只有bcl-2与其他肿瘤参数有微弱关联，且有5年生存率提高的趋势。目前，没有足够的证据支持将分子标志物用作MBC的独立预后标志物。
